Division of General Surgery, Department of Colorectal Surgery, Hospital Universitario Central de Asturias (HUCA), Avenida de Roma s/n, 33011, Oviedo, Spain.
Health Research Institute of the Principality of Asturias (ISPA), Asturias, Spain.
Ann Surg Oncol. 2021 Dec;28(13):8823-8837. doi: 10.1245/s10434-021-10186-9. Epub 2021 Jun 4.
Previous systematic reviews suggest that the implementation of 'complete mesocolon excision' (CME) for colon tumors entails better specimen quality but with limited long-term outcomes. We performed a meta-analysis to compare the pathological, perioperative, and oncological results of CME with conventional surgery (CS) in primary colon cancer.
Embase, MEDLINE and CENTRAL databases were searched using Medical Subject Headings for CME and D3 lymphadenectomy. The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A total of 18,989 patients from 27 studies were included. Postoperative complications were higher in the CME group (relative risk [RR] 1.13, 95% confidence interval [CI] 1.04-1.22, I = 0%), while no differences were observed in terms of anastomotic leak (I = 0%) or perioperative mortality (I = 49%). CME was associated with a higher number of lymph nodes harvested (I = 95%), distance to high tie (I = 65%), bowel length (I = 0%), and mesentery area (I = 95%). CME also had positive effects on 3- and 5-year overall survival (RR 1.09, 95% CI 1.04-1.15, I = 88%; and RR 1.05, 95% CI 1.02-1.08, I = 62%, respectively) and 3-year disease-free survival (RR 1.10, 95% CI 1.04-1.17, I = 22%), as well as decreased local (RR 0.35, 95% CI 0.24-0.51, I = 51%) and distant recurrences (RR 0.71, 95% CI 0.60-0.85, I = 34%).
Limited evidence suggests that CME improves oncological outcomes with a higher postoperative adverse events rate but no increase in anastomotic leak rate or perioperative mortality, compared with CS.
先前的系统评价表明,对于结肠肿瘤,实施“完整结肠系膜切除术”(CME)可获得更好的标本质量,但长期结果有限。我们进行了一项荟萃分析,比较了 CME 与传统手术(CS)在原发性结肠癌中的病理、围手术期和肿瘤学结果。
使用医学主题词(MeSH)在 Embase、MEDLINE 和 CENTRAL 数据库中搜索 CME 和 D3 淋巴结清扫术。系统评价按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行。
共有 27 项研究的 18989 名患者纳入研究。CME 组术后并发症发生率较高(相对风险 [RR] 1.13,95%置信区间 [CI] 1.04-1.22,I=0%),但吻合口漏(I=0%)或围手术期死亡率(I=49%)无差异。CME 与更多的淋巴结检出(I=95%)、高位结扎距离(I=65%)、肠长度(I=0%)和肠系膜面积(I=95%)有关。CME 还对 3 年和 5 年总生存率(RR 1.09,95%CI 1.04-1.15,I=88%;和 RR 1.05,95%CI 1.02-1.08,I=62%)和 3 年无病生存率(RR 1.10,95%CI 1.04-1.17,I=22%)有积极影响,并降低了局部(RR 0.35,95%CI 0.24-0.51,I=51%)和远处复发(RR 0.71,95%CI 0.60-0.85,I=34%)的风险。
有限的证据表明,与 CS 相比,CME 可改善肿瘤学结果,但术后不良事件发生率较高,吻合口漏发生率或围手术期死亡率无增加。